Skip to main content

Table 4 Univariate and multivariate regression analyses of variables identified LDL-C/apoB ratio

From: Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study

Variables

Univariate

Multivariate 1

Multivariate 2

Multivariate 3

Multivariate 4

Multivariate 5

r

p value

β

p value

β

p value

β

p value

β

p value

β

p value

All cases (n = 684)

 Age

−0.151

< 0.0001

−0.104

0.008

−0.125

0.001

−0.134

0.001

−0.144

0.0002

−0.141

0.0001

 Gender

−0.196

< 0.0001

−0.135

0.0003

−0.119

0.0005

−0.131

0.0007

−0.113

0.003

−0.079

0.027

 BMI

−0.134

0.001

0.020

0.622

0.002

0.960

0.011

0.797

0.018

0.646

0.048

0.201

 Cigarette smoking

−0.054

0.163

          

 Hypertension

−0.154

< 0.0001

−0.014

0.707

−0.009

0.814

−0.019

0.630

−0.024

0.527

−0.008

0.822

 Dyslipidemia

−0.244

< 0.0001

−0.047

0.311

−0.082

−0.068

−0.084

0.087

−0.052

0.266

−0.010

0.819

 Diabetes mellitus

−0.150

< 0.0001

0.009

0.856

0.027

0.582

<0.0001

0.994

0.004

0.932

−0.009

0.849

 HbA1c

−0.131

0.0008

0.01

0.836

0.025

0.612

0.025

0.630

0.032

0.522

0.029

0.542

 HDL-C

0.299

< 0.0001

0.155

0.007

0.045

0.295

0.181

< 0.0001

0.236

< 0.0001

0.344

< 0.0001

 Statins use

−0.220

< 0.0001

−0.131

0.003

−0.109

0.010

−0.138

0.003

−0.108

0.014

−0.147

0.0004

 Fibrates use

−0.122

0.002

−0.075

0.037

−0.059

0.088

−0.081

0.029

0.069

0.052

−0.063

0.061

 Glitazone use

−0.035

0.368

          

 TRLs-related markers

  TG*

0.446

0.0001

0.345

0.0001

  VLDL

0.502

0.0001

0.424

0.0001

  RLP-C*

0.304

0.001

0.240

0.0001

  apo C-II

0.353

0.0001

0.323

0.0001

  

  apo C-III

0.401

0.0001

0.045

0.0001

 Inflammatory markers

  WBC count

−0.130

0.0007

−0.036

0.339

−0.031

0.387

−0.053

0.170

−0.065

0.082

−0.035

0.318

  hs-CRP*

−0.110

0.005

0.002

0.956

−0.018

0.636

0.008

0.843

0.014

0.720

0.026

0.472

LDL-C < 100 mg.dL (n = 264)

 Age

−0.095

0.124

          

 Gender

0.183

0.003

−0.049

0.358

−0.052

0.318

−0.058

0.290

−0.040

0.437

−0.007

0.878

 BMI

−0.259

< 0.0001

−0.065

0.258

−0.076

0.174

−0.074

0.210

−0.044

0.426

−0.019

0.723

 Scigarette smoking

−0.045

0.477

          

 Hypertension

−0.207

0.0008

−0.033

0.562

−0.042

0.448

−0.035

0.555

−0.024

0.656

−0.025

0.625

 Dyslipidemia

−0.351

< 0.0001

−0.151

0.042

−0.189

0.009

−0.187

0.017

−0.162

0.023

−0.098

0.149

 Diabetes mellitus

−0.138

0.025

0.056

0.433

0.068

0.331

0.056

0.445

0.023

0.733

−0.006

0.926

 HbA1c

−0.154

0.013

−0.025

0.732

−0.037

0.598

−0.017

0.820

0.014

0.839

−0.001

0.987

 HDL-C

0.301

< 0.0001

0.055

0.347

−0.002

0.969

0.131

0.026

0.213

0.0001

0.313

< 0.0001

 Statins use

−0.193

0.002

0.005

0.937

−0.002

0.970

−0.038

0.583

0.007

0.917

−0.049

0.416

 Fibrates use

−0.269

< 0.0001

−0.167

0.002

−0.147

0.005

−0.196

0.0003

−0.156

0.002

−0.109

0.025

 Glitazone use

0.024

0.702

          

 TRLs-related markers

  TG*

0.601

0.0001

0.436

0.0001

  VLDL

0.606

0.0001

0.464

0.0001

  RLP-C*

0.502

0.0001

0.349

0.0001

  apo C-II

0.577

0.0001

0.453

0.0001

  apo C-III

0.591

0.0001

0.544

0.0001

 Inflammatory markers

  WBC count

−0.182

0.003

−0.078

0.144

−0.079

0.134

−0.106

0.056

−0.097

0.058

−0.075

0.123

  hs-CRP*

−0.083

0.184

          

Lipid-modifying treatment (n = 335)

 Age

−0.138

0.012

−0.176

0.001

−0.170

0.001

−0.186

0.001

−0.222

< 0.0001

−0.231

< 0.0001

 Gender

−0.201

0.0002

−0.176

0.002

−0.143

0.008

−0.162

0.006

−0.166

0.003

−0.131

0.014

 BMI

0.004

0.939

          

 Scigarette smoking

−0.036

0.510

          

 Hypertension

−0.144

0.009

−0.075

0.155

−0.077

0.129

−0.077

0.164

−0.075

0.161

−0.054

0.281

 Dyslipidemia

−0.120

0.029

−0.033

0.534

−0.042

0.406

−0.039

0.480

−0.028

0.604

−0.029

0.563

 Diabetes mellitus

−0.094

0.089

          

 HbA1c

−0.116

0.039

−0.065

0.218

−0.056

0.268

−0.056

0.309

−0.033

0.540

−0.044

0.381

 HDL-C

0.220

< 0.0001

0.027

0.635

−0.043

0.449

0.092

0.113

0.123

0.027

0.203

0.0002

 Statins use

0.019

0.731

          

 Fibrates use

−0.132

0.016

−0.088

0.945

−0.072

0.153

−0.108

0.051

−0.092

0.083

−0.066

0.187

 Glitazone use

0.014

0.800

          

 TRLs-related markers

  TG*

0.368

0.0001

0.299

0.0001

  VLDL

0.468

0.0001

0.424

0.0001

  RLP-C*

0.208

0.0002

0.133

0.019

  apo C-II

0.253

0.0001

0.249

0.0001

  apo C-III

0.384

0.0001

0.416

0.0001

 Inflammatory markers

  WBC count

−0.114

0.037

−0.038

0.495

−0.040

0.441

−0.075

0.192

−0.060

0.278

−0.006

0.916

  hs-CRP*

−0.060

0.276

          

No Lipid-modifying treatment (n = 349)

 Age

−0.105

0.051

          

 Gender

−0.203

0.0002

−0.073

0.163

−0.063

0.218

−0.072

0.178

−0.036

0.282

−0.008

0.867

 BMI

−0.213

< 0.0001

0.041

0.462

0.008

0.879

0.027

0.637

0.036

0.508

0.074

0.158

 Scigarette smoking

−0.087

0.119

          

 Hypertension

−0.084

0.121

          

 Dyslipidemia

−0.153

0.005

0.002

0.965

−0.039

0.475

−0.009

0.88

0.020

0.725

0.070

0.190

 Diabetes mellitus

−0.116

0.032

−0.03

0.575

0.006

0.916

−0.047

0.405

−0.040

0.451

−0.005

0.267

 HbA1c

−0.078

0.153

          

 HDL−C

0.354

< 0.0001

0.187

0.002

0.112

0.067

0.259

< 0.0001

0.349

< 0.0001

0.480

< 0.0001

 Glitazone use

−0.046

0.392

          

 TRLs-related markers

  TG*

0.490

0.0001

0.420

0.0001

  VLDL

0.518

0.0001

0.446

0.0001

  RLP-C*

0.408

0.0001

0.355

0.0001

  apo C-II

0.403

0.0001

0.417

0.0001

  apo C-III

0.410

0.0001

0.528

0.0001

 Inflammatory markers

  WBC count

−0.140

0.010

−0.012

0.822

0.002

0.968

−0.018

0.736

−0.037

0.471

−0.030

0.528

  hs-CRP*

−0.160

0.003

−0.035

0.511

0.006

0.916

−0.047

0.405

−0.037

0.471

−0.018

0.714

  1. BMI body mass index, eGFR estimated glomelular flow rate; CKD chronic kidney disease, CAD coronary artery disease, AP angina pectoris, OMI old myocardial infarction, Hb hemoglobin, ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, TC total cholesterol, LDL low-density lipoprotein, HDL high-density lipoprotein, TG triglyceride, VLDL very LDL, RLP remnant-like particle, apo apolipoprotein, MDA malondealdehyde-modified, WBC white blood count, hs-CRP high-sensitivity C-reactive protein, r correlation coefficient, β standard partial regression coefficient, * log-transformed value was used; gender (0: female, 1: male); cigarette smoking (0: no, 1: yes); hypertension (0: no. 1: yes); diabetes mellitus (0: no, 1: yes); statins use (0: no. 1: yes); fibrates use (0: no. 1: yes); glitazones use (0: no. 1: yes)